CASI PHARMACEUTICALS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
CASI PHARMACEUTICALS, INC. (CASIF) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$3.44 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-05-15.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-05-15
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | -$3.44M 20-F · filed 2026-05-15 |
| 2024-12-31 | -$1.90M 20-F · filed 2026-05-15 |
| 2023-12-31 | -$28.28M 20-F · filed 2026-05-15 |
| 2022-12-31 | -$7.29M 20-F · filed 2025-03-31 |
| 2021-12-31 | -$10.68M 20-F · filed 2024-03-28 |